Συγγραφείς:
Cherny, N.I.
Sullivan, R.
Dafni, U.
Bogaerts, J.
Kerst, J.M.
Zielinski, C.
Piccart, M.J.
De Vries, E.G.E.
Λέξεις-κλειδιά:
epidermal growth factor receptor; gefitinib; ipilimumab; nivolumab; protein tyrosine kinase inhibitor; trametinib; vemurafenib, adverse outcome; biomedical technology assessment; EGFR gene; feedback system; gene mutation; general condition deterioration; health care utilization; human; Letter; lung cancer; medical decision making; medical society; metastatic melanoma; non small cell lung cancer; oncology; overall survival; peer review; priority journal; progression free survival; public health service; quality of life; risk factor; therapy effect
